|
Media Inquiries
Email
|
|
|
Polyphenon Pharma to Present at the 2009 BIO-Europe Spring Conference
New York, NY, March 13, 2009 – Polyphenon Pharma, an emerging research-based pharmaceutical company, today announced that Mr. Stig Ogata, Executive Vice President and Chief Operating Officer, will present at the 2009 BIO-Europe Spring Conference on Tuesday, March 17, 2009 at 4:40 pm (ET) in Milan, Italy. Mr. Ogata will provide an overview of the Company’s pipeline and an update on its clinical development efforts involving its lead compound, the defined catechin composition, Polyphenon E®.
Polyphenon E is a highly defined catechin composition that is extracted from green tea leaves through a proprietary process. The primary catechin in Polyphenon E, epigallocatechin gallate (EGCG), has been shown to affect many processes in the body related to abnormal cellular activity that can lead to cancer. Preclinical studies indicate that the six principal catechins present in Polyphenon E may have multiple methods of action.
Polyphenon Pharma is a privately held subsidiary of the Japanese company, Mitsui Norin Co., Ltd., which discovered and manufactures Polyphenon E. Headquartered in New York, NY, Polyphenon Pharma focuses on the clinical development of Polyphenon E across a broad spectrum of therapeutic areas in which it has potential activity, including infectious disease/virology, urology, neurology, and oncology.
More information is available at
www.polyphenon-pharma.com. To request a copy of the Company presentation, please contact
Michi.Kato@polyphenon-pharma.com.
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected results of our development. We can provide no assurance that such development will proceed as currently anticipated or that the expected results of such development will be realized. We are subject to various risks, including the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our reliance on collaborative partners, our need for additional capital to fund our operations, our history of losses, and other risks inherent to the biopharmaceutical industry.
# # #
|
